Clinical characteristics at time of enrolment in the ItinérAIR-Sclérodermie registry according to systemic sclerosis subtype. Categorical data are expressed as percentages, continuous data are mean ± SD.
| All | dcSSc | lcSSc | p | |
|---|---|---|---|---|
| Patients, n | 599 | 165 | 434 | |
| Male, % | 16 | 22 | 14 | 0.01 |
| Age, yrs | 55 ± 13 | 53 ± 13 | 55 ± 13 | 0.10 |
| Occupational risks*, % | 11 | 13 | 10 | 0.23 |
| Delay between RP onset and first non-RP clinical symptom, yrs | 6 ± 9 | 3 ± 6 | 7 ± 10 | < 0.0001 |
| Time since first non-RP symptom onset, yrs | 7 ± 7 | 8 ± 7 | 7 ± 7 | 0.09 |
| Age at first non-RP symptom, yrs | 46 ± 14 | 44 ± 14 | 47 ± 14 | 0.008 |
| Never smoker, % | 68 | 67 | 69 | 0.64 |
| Current smoker, % | 12 | 15 | 11 | 0.24 |
| Tobacco consumption (pack/yr)† | 5 ± 12 | 6 ± 16 | 5 ± 10 | 0.18 |
| Rodnan score | 13 ± 11 | 26 ± 12 | 9 ± 5 | < 0.0001 |
| Digital sclerosis score | 7 ± 3 | 9 ± 3 | 6 ± 3 | < 0.0001 |
| TLC < 80% predicted, % | 15 | 23 | 12 | < 0.0001 |
| FVC < 80% predicted, % | 13 | 24 | 8 | < 0.0001 |
| DLCO < 60% predicted, % | 24 | 39 | 19 | < 0.0001 |
↵* Exposure to silicates, solvents, glue, or resin.
↵† Never-smokers assigned a consumption of zero. RP: Raynaud’s phenomenon; dcSSc: diffuse cutaneous systemic sclerosis; DLCO: lung diffusing capacity for carbon monoxide; lcSSc: limited cutaneous systemic sclerosis; TLC: total lung capacity; FVC: forced vital capacity.